Stocks Health care ICCC
NASDAQ · Health careImmucell Corp (ICCC)
Immucell Corp brought in $30.7M of revenue over the twelve months to June 30, 2026, up 8.5% from a year earlier. Net income was $787.4K, a net margin of 2.6%. Operating cash flow minus capital spending left $1.2M of free cash flow in fiscal 2025. At June 30, 2026 it held $8.9M in cash against $8.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Immucell Corp does
Immucell Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker ICCC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $27.6M | -$1M | -$0.12 | $1.2M |
| 2024 | $26.5M | -$2.2M | -$0.26 | -$107.8K |
| 2023 | $17.5M | -$5.8M | -$0.75 | -$6.6M |
| 2022 | $18.6M | -$2.5M | -$0.32 | -$5.5M |
| 2021 | $19.2M | -$78.3K | -$0.01 | -$1.7M |
| 2020 | $15.3M | -$1M | -$0.14 | -$2.8M |
Latest SEC filings
What Immucell Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- July 9, 2026
- June 17, 2026
- June 10, 2026
- May 14, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026
- May 13, 2026Annual report (amended) 10-K/A · period to December 31, 2025
- May 8, 2026
- April 24, 2026Proxy statement DEF 14A
Questions about ICCC
What does Immucell Corp do?
Immucell Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker ICCC.
Is Immucell Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $787.4K on revenue of $30.7M, a net margin of 2.6%.
How much revenue does Immucell Corp make?
Over the twelve months to June 30, 2026 Immucell Corp reported revenue of $30.7M. That is 8.5% more than a year earlier.
When did Immucell Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.
Similar companies
Follow ICCC
Get an email when Immucell Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow ICCC: get an email when it filesWhere the numbers come from
Financial figures are the values Immucell Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.